News | November 23, 2024
Amalgamation of Gujarat Themis Biosyn with Themis Medicare
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
Subscribe To Our Newsletter & Stay Updated
